Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2023-Q2 EPS reported $3.90 revenue$2,089,310,000

Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.
GAAP net income $97.0M (−11.3%), diluted EPS $1.89; non-GAAP EPS $2.69 (−2.9%).
RMS segment revenue $209.9M (+12.6%, organic +13.9%) driven by China model shipments; Manufacturing segment revenue $186.5M (−4.2%).
FY 2023 guidance narrowed: organic revenue growth 5.5%–7.5% (prior 5.0%–7.5%); non-GAAP EPS $10.30–$10.90 (prior $9.90–$10.90).
CEO cites cautious biopharma spending but confidence in differentiated scientific breadth and DSA backlog.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the second quarter of 2023 results: revenue $1.06 billion, EPS $1.89. Guidance reaffirmed.

Period: the second quarter of 2023
Revenue: $1.06 billion
EPS: $1.89
Guidance: reaffirmed
Result: reported results

Exact text from the filing

EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53513759ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--August 9,

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filing history →

Source: SEC EDGAR

accession 0001157523-23-001294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.